Sanofi India Limited (SANOFI.NS)
INR 5950.5
(0.13%)
INR 5950.5
(0.13%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 6.99 Billion INR | -12.1% |
| 2022 | 7.95 Billion INR | -4.73% |
| 2021 | 8.35 Billion INR | 4.49% |
| 2020 | 7.99 Billion INR | -0.32% |
| 2019 | 8.02 Billion INR | 4.89% |
| 2018 | 7.64 Billion INR | 1.88% |
| 2017 | 7.5 Billion INR | -6.69% |
| 2016 | 8.04 Billion INR | 3.47% |
| 2015 | 7.77 Billion INR | 4.81% |
| 2014 | 7.41 Billion INR | 48.92% |
| 2013 | 4.98 Billion INR | 16.6% |
| 2012 | 4.27 Billion INR | 10.69% |
| 2011 | 3.85 Billion INR | -2.11% |
| 2010 | 3.94 Billion INR | 44.13% |
| 2009 | 2.73 Billion INR | 15.8% |
| 2008 | 2.36 Billion INR | 13.19% |
| 2007 | 2.08 Billion INR | -16.52% |
| 2006 | 2.5 Billion INR | 46.23% |
| 2005 | 1.7 Billion INR | 14.3% |
| 2004 | 1.49 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2024 Q2 | 6.75 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 7.73 Billion INR | 0.0% |
| 2023 FY | 6.99 Billion INR | -12.1% |
| 2023 Q4 | 6.99 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 7.95 Billion INR | 0.0% |
| 2022 FY | 7.95 Billion INR | -4.73% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 7.21 Billion INR | 0.0% |
| 2021 Q4 | 8.35 Billion INR | 0.0% |
| 2021 Q2 | 8.84 Billion INR | 0.0% |
| 2021 FY | 8.35 Billion INR | 4.49% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q4 | 7.99 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q2 | 8.19 Billion INR | 0.0% |
| 2020 FY | 7.99 Billion INR | -0.32% |
| 2020 Q3 | - INR | -100.0% |
| 2019 Q2 | 7.6 Billion INR | 0.0% |
| 2019 FY | 8.02 Billion INR | 4.89% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q4 | 8.02 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2018 FY | 7.64 Billion INR | 1.88% |
| 2018 Q2 | 7.66 Billion INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q4 | 7.64 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2017 Q4 | 7.5 Billion INR | 0.0% |
| 2017 FY | 7.5 Billion INR | -6.69% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 7.18 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2016 Q4 | 8.04 Billion INR | 0.0% |
| 2016 FY | 8.04 Billion INR | 3.47% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q2 | 6.88 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q4 | 7.77 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 6.59 Billion INR | 0.0% |
| 2015 FY | 7.77 Billion INR | 4.81% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 4.4 Billion INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 FY | 7.41 Billion INR | 48.92% |
| 2014 Q4 | 7.41 Billion INR | 0.0% |
| 2013 Q2 | 3.81 Billion INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 FY | 4.98 Billion INR | 16.6% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q4 | 4.98 Billion INR | 0.0% |
| 2012 Q3 | - INR | -100.0% |
| 2012 FY | 4.27 Billion INR | 10.69% |
| 2012 Q4 | 4.27 Billion INR | 0.0% |
| 2012 Q2 | 3.2 Billion INR | 0.0% |
| 2011 FY | 3.85 Billion INR | -2.11% |
| 2011 Q4 | 3.85 Billion INR | 0.0% |
| 2010 FY | 3.94 Billion INR | 44.13% |
| 2009 FY | 2.73 Billion INR | 15.8% |
| 2008 FY | 2.36 Billion INR | 13.19% |
| 2007 FY | 2.08 Billion INR | -16.52% |
| 2006 FY | 2.5 Billion INR | 46.23% |
| 2005 FY | 1.7 Billion INR | 14.3% |
| 2004 FY | 1.49 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Abbott India Limited | 14.94 Billion INR | 53.191% |
| Cipla Limited | 59.15 Billion INR | 88.173% |
| Gland Pharma Limited | 19.37 Billion INR | 63.89% |
| GlaxoSmithKline Pharmaceuticals Limited | 17.96 Billion INR | 61.049% |
| Kopran Limited | 2.52 Billion INR | -177.618% |
| Marksans Pharma Limited | 5.95 Billion INR | -17.571% |
| NGL Fine-Chem Limited | 929.03 Million INR | -653.036% |
| Pfizer Limited | 6.33 Billion INR | -10.479% |
| SMS Pharmaceuticals Limited | 4.97 Billion INR | -40.549% |
| TTK Healthcare Limited | 1.99 Billion INR | -250.368% |